FDA Says Baxter's Round Lake Plant Found Cephalosporin In Areas Meant To Be Free Of It
A warning letter lists four sets of manufacturing violations at the Illinois injectables plant and asks for independent assessments.
The FDA made public on Tuesday a warning letter it sent Baxter International on Sept. 29, saying its Round Lake, Illinois, injectables plant broke current good manufacturing practice rules and that its drugs are therefore adulterated. The letter, addressed to Andrew Hider, lists four sets of violations after an inspection from March 23 to April 2, 2026.
What the letter says
The FDA identified the site as Baxter Healthcare Corporation, FEI 1416980. Its first finding: since January 2025, Baxter's environmental monitoring detected cephalosporin, an antibiotic, in several instances and in multiple areas of the side of the building meant to be free of it. The agency said the plant's wall and dedicated air handling did not amount to complete separation.
The FDA also said Baxter's monitoring was too thin in number and location, and that the company mistakenly discarded multiple failing cephalosporin samples before further analysis. It said no safe level of beta-lactam contamination has been determined to be tolerable.
On sterile manufacturing, the letter cites repeated positive biological indicators during re-qualification runs, simulations that did not represent worst-case conditions, and turbulent airflow where critical steps happen. The FDA also noted a history of sporadic sterility test positives since 2013 and persistent particulate contamination issues.
On particulates, the FDA said Baxter's manual visual inspection was inadequate and that operators were not properly qualified. It cited a May 9, 2025, returned cefazolin sample confirmed to hold foreign particulate consistent with cardboard.
The letter says Baxter agreed on July 17, 2026, to recall cefazolin Lot LD175708 "only after the Agency contacted you."
The fourth finding covers investigations. The FDA said leak rates rose each year from 2023 to 2026 while the number of non-conformance reports opened fell. It also said Baxter invalidated a 2025 cefazolin sterility result without adequate justification and released the lot in July 2025.
What Baxter must do
The FDA reviewed Baxter's April 23, 2026, response to the inspection findings and called it inadequate on several points, including how complete separation would be ensured. The letter does not carry a fine, a shutdown or a recall order.
It asks for independent risk assessments, detailed remediation plans with timelines, and independent reviews of visual inspection, airflow, media fills and the quality unit. It also requests an assessment of each in-date sterile injectable lot distributed from the plant.
The agency warned that failing to adequately address the violations may bring regulatory or legal action without further notice, including seizure and injunction. Baxter's market value was $12.9 billion as of Tuesday morning's report.
The FDA said the list is not all-inclusive, and it wants the independent assessments and remediation timelines in Baxter's response.
Sources
- Warning letter — Baxter International Inc. (MARCS-CMS 733231) — U.S. Food and Drug Administration